Living After a Rare Cancer of the Ovary: Chronic Fatigue, Quality of Life and Late Effects of Chemotherapy

NCT ID: NCT03418844

Last Updated: 2025-09-22

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Clinical Phase

NA

Total Enrollment

268 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-05-07

Study Completion Date

2025-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

While they are documented in patients in remission of testicular cancer, the sequelae of chemotherapy and the impact of the disease and its treatments on the living conditions and QoL of women in remission of rare ovarian cancer remain poorly explored.

The coordinator therefore propose a national 2-step case-control study to evaluate 1) chronic fatigue and QoL and 2) chemotherapy-related sequelae in adult patients in remission of surgery-treated TGMO or TSCS (conservative or not) supplemented with chemotherapy

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Germ Cell Tumor Sex Cord Stromal Tumor Malignant Non-epithelial Ovarian Tumors

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Patients and healthy volunteers will complete several self-questionnaires on living conditions and quality of life. Patients will also perform a cardiac, pulmonary, auditory and biological assessment
Primary Study Purpose

OTHER

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Interest group (patients treated with chemotherapy)

Patients will complete several self-questionnaires on living conditions and quality of life. They will also perform a cardiac, pulmonary, auditory and biological assessment

Group Type OTHER

Self-questionnaires of living conditions and quality of life

Intervention Type OTHER

Patients will complete self-questionnaires of living conditions and quality of life (MFI-20, FACT-G/FACT-O, FACT/COG-NTX, FACT-Cog, HADS, Insomnia Severity Index , International Physical Activity Questionnaire)

Cardiac, pulmonary, auditory and biological assessment

Intervention Type DIAGNOSTIC_TEST

Patients will perform :

* Cardiac assesments (ECG, Carotid and humeral Doppler ultrasound, Trans-thoracic echocardiography 2D and 3D)
* Pulmonary and auditory assesment ( Respiratory Functional Exploration, Tonal audiogram)
* Blood tests

Patient control group (patients not treated with chemotherapy)

Patients will complete several self-questionnaires on living conditions and quality of life. They will also perform a cardiac, pulmonary, auditory and biological assessment

Group Type OTHER

Self-questionnaires of living conditions and quality of life

Intervention Type OTHER

Patients will complete self-questionnaires of living conditions and quality of life (MFI-20, FACT-G/FACT-O, FACT/COG-NTX, FACT-Cog, HADS, Insomnia Severity Index , International Physical Activity Questionnaire)

Cardiac, pulmonary, auditory and biological assessment

Intervention Type DIAGNOSTIC_TEST

Patients will perform :

* Cardiac assesments (ECG, Carotid and humeral Doppler ultrasound, Trans-thoracic echocardiography 2D and 3D)
* Pulmonary and auditory assesment ( Respiratory Functional Exploration, Tonal audiogram)
* Blood tests

Healthy volunteers

Healthy volunteers will complete several self-questionnaires on living conditions and quality of life.

Group Type OTHER

Self-questionnaires of living conditions and quality of life

Intervention Type OTHER

Patients will complete self-questionnaires of living conditions and quality of life (MFI-20, FACT-G/FACT-O, FACT/COG-NTX, FACT-Cog, HADS, Insomnia Severity Index , International Physical Activity Questionnaire)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Self-questionnaires of living conditions and quality of life

Patients will complete self-questionnaires of living conditions and quality of life (MFI-20, FACT-G/FACT-O, FACT/COG-NTX, FACT-Cog, HADS, Insomnia Severity Index , International Physical Activity Questionnaire)

Intervention Type OTHER

Cardiac, pulmonary, auditory and biological assessment

Patients will perform :

* Cardiac assesments (ECG, Carotid and humeral Doppler ultrasound, Trans-thoracic echocardiography 2D and 3D)
* Pulmonary and auditory assesment ( Respiratory Functional Exploration, Tonal audiogram)
* Blood tests

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age\> 18 years;
* Patient with an ovarian malignant germ cell tumor (TGMO) or a stroma tumor and / or sex cords (TSCS) treated optimally;
* Patient who has had surgery and chemotherapy (interest group) or only a surgery (control group);
* Patient in remission more than 2 years after the end of the initial treatment;
* Relapse authorized if remission more than 2 years after the end of the treatment;
* Patient with no other cancers (with the exception of basal cell skin carcinomas, in situ cancers of the breast and cervix);
* Patient having signed his consent to participate

Exclusion Criteria

* Pregnant or breastfeeding woman;
* Psychiatric pathology that may disrupt the course of the study or prevent the interpretation of results;
* Person deprived of liberty;
* Major subject to a legal protection measure or unable to express his consent.
Minimum Eligible Age

18 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

ARCAGY/ GINECO GROUP

OTHER

Sponsor Role collaborator

Centre Francois Baclesse

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Florence JOLY

Role: PRINCIPAL_INVESTIGATOR

Centre François Baclesse

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

HEGP

Paris, Paris, France

Site Status

Centre Paul Papin

Angers, , France

Site Status

CHU Besançon Jean MINJOZ

Besançon, , France

Site Status

Institut Bergonié

Bordeaux, , France

Site Status

CH Fleyriat

Bourg-en-Bresse, , France

Site Status

Centre François Baclesse

Caen, , France

Site Status

Centre Jean Perrin

Clermont-Ferrand, , France

Site Status

Centre Léon Berard

Lyon, , France

Site Status

Institut Paoli Calmettes

Marseille, , France

Site Status

Centre Catherine de Sienne

Nantes, , France

Site Status

Institut de Cancérologie de l'Ouest

Nantes, , France

Site Status

GH Cochin Broca Hôtel-Dieu

Paris, , France

Site Status

Hôpital Diaconesses-Croix St Simon

Paris, , France

Site Status

Institut Curie,

Paris, , France

Site Status

Institut Gustave Roussy

Paris, , France

Site Status

CHU Poitiers

Poitiers, , France

Site Status

Institut Jean Godinot

Reims, , France

Site Status

Institut Rennais de Cancérologie

Rennes, , France

Site Status

CHRU Stasbourg Hôpital Civil

Strasbourg, , France

Site Status

Countries

Review the countries where the study has at least one active or historical site.

France

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

VIVROVAIRE TR

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Women Surviving Ovarian Cancer
NCT00596349 COMPLETED